Ref ID: 19275
Author:
K. Hirano, K. Izumikawa, T. Takazono, K. Kosai, Y. Morinaga, S. Kurihara, S. Nakamura, Y. Imamura, T. Miyazaki, M. Tsukamoto, H. Kakeya, K. Yanagihara, T. Tashiro, S. Kohno
Author address:
Nagasaki Univ., Nagasaki, JAPAN.
Full conference title:
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy
Date: 10 September 2014
Abstract:
Background: Fungal infection is one of the most serious problems in immunocompromised patients during the medication of anticancer and immunosuppressant drugs, and among HIV/AIDS patients. Invasive pulmonary aspergillosis(IPA) results in significant mortality in severely immunocompromised patients. We found the case of itraconazole (ITCZ) resistant Aspergillus fumigatus strains isolated.Targeted intrapulmonary delivery of antifungals has the potential to reduce systemic toxicity and improve treatment efficacy as well as prophylaxis. Therefore, we investigated inhalation of ITCZ treatment against IPA model with ITCZ-low susceptible A.fumigatus. Methods: A.fumigatus MF367 and MF469 were clinically obtained from a patient admitted to the Nagasaki University Hospital. The MIC of MF367 was 0.5mg/L and that of MF469 was 8.0mg/L. Six-week-old female ICR mice were immunosuppressed and then challenged on day 0 with 5x 104 conidia of A.fumigatus intratracheally for monitoring of survival for 14 days. Mice were assigned into the following groups:
control mice challenged with MF367 or MF469 without
treatment, the mice challenged with MF367 or MF469
receiving ITCZ oral administration (20mg,40mg,80mg/kg),
and the mice challenged with MF367 or MF469 receiving
ITCZ inhalation (5ml mixture solution of ITCZ and saline of
20%, 40%, 80%,100%). Results: The survival rate of MF-
367-infected mice treated with nebulized ITCZ (40%,
80%,100%) were 63%, 71%,and 80%, respectively, and
that of ITCZ (80mg/kg) oral administration was 62%. The
survival rate of MF-469-infected mice treated with
nebulized ITCZ (80%,100%) were 60%, and 71%,
respectively, and that of ITCZ (80mg/kg) oral
administration was 50%. The survival rates of the group of
mice receiving nebulized ITCZ were significantly higher
than those of the group of mice receiving oral ITCZ
administration. Additionally, MF-367 (ITCZ-susceptible)-
infected mice were more sensitive to nebulized ITCZ
compared to MF-469 (ITCZ-low susceptible)-infected mice.
Conclusions: Our result indicated the possibility of
inhalation of ITCZ administration is effective to IPA with
ITCZ-low susceptible A.fumigatus strain.
Abstract Number: NULL
Conference Year: 2013
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a